Stockreport

Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

ALDER BIOPHARMACEUTICALS INC  (ALDR) 
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
PDF - Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patie [Read more]